Tamoxifen (Soltamox/Nolvadex®; AstraZeneca), an antagonist of the estrogen receptor ? in ER?-positive breast cancer has been effective in most patients.…
The immune system has the ability to recognize tumors and to stop or control their development through a process known…
For more free video updates go to www.oncologyeducation.com Incorporation of Bv into anthracycline and taxane containing adjuvant therapy does not…
To view more free videos – visit www.oncologyeducation.com Profiling of protein expression, gene copy variations and mutations identified clinically relevant…
For additional free GI/Colorectal Cancer video updates, please go to www.oncologyeducation.com Chemo/CET and chemo/BV equivalent in OS in pts KRAS…
Dr Kenneth Anderson (Dana Farber Cancer Institute, Boston, USA) chairs a discussion with Prof Gareth Morgan (The Royal Marsden Hospital,…
Dr Anderson (Dana Farber Cancer Institute, Boston, USA) chairs a discussion with Prof Palumbo (University of Torina, Torina, Italy), Prof…
Prof Keith Stewart (Mayo Clinic, Scottsdale, USA) chairs a discussion with Prof Gareth Morgan (The Royal Marsden Hospital, London, UK),…
Dr Ola Landgren from Memorial Sloan Kettering, New York, USA, tells the European Medical Journal about the possible enormous value…
Dr Ola Landgren from Memorial Sloan Kettering, New York, USA, summarises recent plethora of data in patients with newly diagnosed…
Dr Ola Landgren from Memorial Sloan Kettering, New York, USA, summarises recent plethora of data in patients with newly diagnosed…
Dr Ola Landgren from Memorial Sloan Kettering, New York, USA, speaks to the European Medical Journal from the 19th Congress…
Speaking to the European Medical Journal from the 19th Congress of the European Haematology Association (EHA) meeting, Prof. John Seymour…
Dr Kenneth Anderson, Multiple Myeloma Boston 2014 congress round-up
Prof. Peter Hillmen from Leeds Teaching Hospital, Leeds, UK, gives an update on the phase III results from the RESONATE…
Speaking to EMJ from the 19th Congress of the European Hematology Association (EHA 19) meeting, Prof. Paul Richardson , Dana-Farber…
Prof. Simon Rule from Plymouth Hospital, UK, discusses data presented at EHA19 on the second-generation oral BTK inhibitor, ONO-4059. One…
Prof. Valeria Santini, University of Florence Medical School, Italy, highlights novel mutational and genetic studies in MDS presented atEHA19 which…
Prof. Stephan Stilgenbauer from University of Ulm, Germany, defines ultra high-risk CLL (chronic lymphocytic leukemia) and comments on its implications…
Held annually in South Florida every January, The Symposium on Clinical Interventional Oncology (CIO) features a concentrated 2-day program renowned…
When it comes to EGFR and lung cancer, is a mutation good or bad? Dr. Joel Neal of Stanford University…
Prof David Cameron from The Edinburgh Cancer Research Centre is committed to identifying potential new approaches to treating and preventing…
A retrospective study of the effect of extending mammography to age 75 was performed in the Netherlands to use data…
A detailed analysis of risk factors including genomic markers of women with breast cancer has revealed that three-year mammographic screening…
A massive Oxford meta-analysis they have completed has shown that adjuvant radiotherapy gives absolute benefits in terms of progression-free and…
Dr Poortmans presented a late breaking abstract at a workshop on the regional control of breast cancer, along with speakers…
Dr. Mark Socinski is a Professor of Medicine, University of Pittsburgh School of Medicine. In this video, he answers common…
7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna, 29 marzo 2014
Gestione degli effetti collaterali delle terapie e delle complicanze post-chirurgiche 7 ° Riunione Nazionale AIG Associazione Italiana GIST Onlus Bologna,…
Stato dell’arte e ricerca clinica attuale (SECONDA PARTE) 7 ° Riunione Nazionale AIG Associazione Italiana GIST Onlus Bologna 29 marzo…
Il percorso della ricerca nei GIST in laboratorio. 7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna, 29 marzo 2014
7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna, 29 marzo 2014
Caso clinico 3: terapia con Regorafenib in terza linea di trattamento. 7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna,…
7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna, 29 marzo 2014
Don Sharpe talks to Terri Guidi, MBA of Oncology Management and Consulting about a real life case study of an…
Don Sharpe sits down with Ted Okon the Executive Director of The Community Oncology Alliance and they talk about what’s…
Don Sharpe talks to Ricky Newton, CPA of Cancer Specialists of Tidewater about how to understand the business issue of…
Don Sharpe talks to Dr. Jeff Vacirca, MD of North Shore Hematology and Oncology concerning the Effects of Sequestration to…
Don Sharpe of OBR interviews Dr. Ira Klein, MD where he asks What is Gene Forward and Gene Backward?
Don Sharpe sits down with Dr. Brian Van Tine, MD PhD or Washington University to talk about Management and Treatment…
Don Sharpe discusses the Payer Perspective on Molecular Testing with Dr. Micheal Kolodziej, MD from Aetna at the COA annual…
Don Sharpe of OBR talks about the variances in genetic testing and how that may affect health care decisions with…
Don Sharpe talks about Molecular Testing for Cancer from a Payer Perspective with Dr. Sundeep Reddy, MD (Caris Life Sciences)…
Don Sharpe of OBR discusses the topic What’s Making Your Oncologist Sick? with Dr. Joseph Lynch, MD at the COA…
Don Sharpe talks to Rebecca Bechhold, MD about Integrating Palliative Care and Oncology from the COA annual meeting in Orlando.
Don Sharpe of OBR discusses The Genetic Science Behind Heredity Colon Cancer Syndromes with Dr. Larry Geier, MD at the…
Don Sharpe of OBR discusses The Medical Home past and future with Bo Gamble, Director of Strategic Practice Initiatives, Community…
Don Sharpe of OBR discusses how an oncology practice get’s started with The Medical Home model and the implemenation process…
Don Sharpe of OBR discusses the progress for payers who are using The Medical Home model with Gordon Kuntz of…
Don Sharpe of OBR talks to Dr. Daniel McKeller, MD of the Commission on Cancer about the report on The…